Pacific Biosciences of Californ vs Pfizer, Inc. — Stock Comparison
Pacific Biosciences of Californ (PACB) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Pfizer, Inc. clearly outscores Pacific Biosciences of Californ on Q·Score (6.4 vs 4.5 out of 10), led by Quality (6.4 vs 0.2) and Valuation (7.7 vs 6.3). Pacific Biosciences of Californ scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst consensus targets imply greater upside for PACB (+75.6%) than for PFE (+15.8%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $2.46 is 76% above current price.
⚠ currently unprofitable (-80% margin).
Forward P/E of 8.9× is low relative to sector peers.
⚠ earnings contracting 10% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
PACB vs PFE: which stock scores better overall?
Based on Q·Score, Pfizer, Inc. (PFE) scores 6.4/10 versus Pacific Biosciences of Californ (PACB) at 4.5/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: PACB or PFE?
Pacific Biosciences of Californ (PACB) scores higher on Growth (5.8/10 vs 5.1/10). Pacific Biosciences of Californ reports revenue growth (0.1% YoY) while Pfizer, Inc. reports (5.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is PACB or PFE more attractively valued?
Pfizer, Inc. (PFE) scores higher on Valuation (7.7/10 vs 6.3/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about PACB vs PFE?
There are 6 analysts covering PACB with a consensus price target of $2.46, and 27 analysts covering PFE with a consensus target of $29.19. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: PACB or PFE?
Pfizer, Inc. (PFE) scores higher on Quality (6.4/10 vs 0.2/10). Net profit margin: PACB at -80.3%, PFE at 11.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: PACB or PFE?
Pfizer, Inc. (PFE) scores higher on Financial Health (7/10 vs 5.7/10). Market beta: PACB at 2.32, PFE at 0.29. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of PACB and PFE?
Pacific Biosciences of Californ (PACB) has a market capitalisation of $435M, while Pfizer, Inc. (PFE) has a market cap of $143.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do PACB or PFE pay dividends?
PACB does not currently pay a dividend, while PFE pays a dividend yield of 6.61%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →